126 related articles for article (PubMed ID: 36265128)
21. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
[TBL] [Abstract][Full Text] [Related]
22. Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Smith CIE; Zain R; Österborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Scand J Immunol; 2022 Apr; 95(4):e13153. PubMed ID: 35244285
[TBL] [Abstract][Full Text] [Related]
23. Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia.
Puła B; Pruszczyk K; Pietrusza E; Morawska M; Piszczek W; Kalicińska E; Szeremet A; Tryc-Szponder J; Wąsik-Szczepanek E; Drozd-Sokołowska J; Krzemień H; Rejus A; Gajewska M; Wiśniewski K; Wysocki M; Majeranowski A; Paszkiewicz-Kozik E; Steckiewicz P; Szukalski Ł; Bołkun Ł; Długosz-Danecka M; Giannopoulos K; Jamroziak K; Lech-Marańda E; Hus I
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158826
[TBL] [Abstract][Full Text] [Related]
24. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.
; Pinato DJ; Patel M; Scotti L; Colomba E; Dolly S; Loizidou A; Chester J; Mukherjee U; Zambelli A; Dalla Pria A; Aguilar-Company J; Bower M; Salazar R; Bertuzzi A; Brunet J; Lambertini M; Tagliamento M; Pous A; Sita-Lumsden A; Srikandarajah K; Colomba J; Pommeret F; Seguí E; Generali D; Grisanti S; Pedrazzoli P; Rizzo G; Libertini M; Moss C; Evans JS; Russell B; Harbeck N; Vincenzi B; Biello F; Bertulli R; Ottaviani D; Liñan R; Rossi S; Carmona-García MC; Tondini C; Fox L; Baggi A; Fotia V; Parisi A; Porzio G; Queirolo P; Cruz CA; Saoudi-Gonzalez N; Felip E; Roqué Lloveras A; Newsom-Davis T; Sharkey R; Roldán E; Reyes R; Zoratto F; Earnshaw I; Ferrante D; Marco-Hernández J; Ruiz-Camps I; Gaidano G; Patriarca A; Bruna R; Sureda A; Martinez-Vila C; Sanchez de Torre A; Berardi R; Giusti R; Mazzoni F; Guida A; Rimassa L; Chiudinelli L; Franchi M; Krengli M; Santoro A; Prat A; Tabernero J; Van Hemelrijck M; Diamantis N; Gennari A; Cortellini A
JAMA Oncol; 2022 Jan; 8(1):114-122. PubMed ID: 34817562
[TBL] [Abstract][Full Text] [Related]
25. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Niemann CU; da Cunha-Bang C; Helleberg M; Ostrowski SR; Brieghel C
Blood; 2022 Aug; 140(5):445-450. PubMed ID: 35588468
[TBL] [Abstract][Full Text] [Related]
26. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
27. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study.
Nomah DK; Reyes-Urueña J; Díaz Y; Moreno S; Aceiton J; Bruguera A; Vivanco-Hidalgo RM; Llibre JM; Domingo P; Falcó V; Imaz A; Cortés C; Force L; Letang E; Vilaró I; Casabona J; Miro JM;
Lancet HIV; 2021 Nov; 8(11):e701-e710. PubMed ID: 34655549
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
Panovská A; Doubek M; Brychtová Y; Mayer J
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):297-300. PubMed ID: 20709668
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
[TBL] [Abstract][Full Text] [Related]
30. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Kochneva ОL; Kislova M; Zhelnova EI; Petrenko AA; Baryakh EA; Yatskov KV; Dmitrieva EA; Misurina EN; Nikitin KE; Vasilieva EJ; Samsonova IV; Ptushkin VV; Baranova A; Nikitin EA
Leuk Lymphoma; 2022 Jul; 63(7):1607-1616. PubMed ID: 35156528
[TBL] [Abstract][Full Text] [Related]
32. Chronic Lymphocytic Leukemia Concomitant with COVID 19: A Case Report.
Ali E; Badawi M; Abdelmahmuod E; Kohla S; Yassin MA
Am J Case Rep; 2020 Oct; 21():e926062. PubMed ID: 33098641
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
34. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
35. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Thibaud S; Tremblay D; Bhalla S; Zimmerman B; Sigel K; Gabrilove J
Br J Haematol; 2020 Jul; 190(2):e73-e76. PubMed ID: 32433778
[No Abstract] [Full Text] [Related]
36. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
37. COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now.
Chatzikonstantinou T; Herishanu Y; Montserrat E; Ghia P; Cuneo A; Foà R; Scarfò L
Cancer J; 2021 Jul-Aug 01; 27(4):328-333. PubMed ID: 34398560
[TBL] [Abstract][Full Text] [Related]
38. A Case of COVID-19-Induced Lymphocytosis in a Patient With Treatment-Naive CLL: Should It Be treated?
Safarpour D; Srinivasan K; Farooqui M; Roth C; Ghouse M
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):69-72. PubMed ID: 33039356
[No Abstract] [Full Text] [Related]
39. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
